FYB208

About Formycon AG

Formycon AG is a Germany-based, publicly traded biopharmaceutical company with a strategic focus on developing and commercializing biosimilars and next-generation biologics. The company has successfully transitioned to a commercial-stage entity, with key biosimilars like FYB201 (ranibizumab) approved in Europe, and has secured significant commercial partnerships for its pipeline. Its strategy centers on a robust in-house development platform, strategic licensing deals with global partners for commercialization, and a pipeline targeting high-value immunology and oncology biologics. Formycon aims to create sustainable value by increasing access to affordable biologic medicines while navigating the complex biosimilar regulatory and market landscape.

Therapeutic Areas